Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | APP | P05067 | 9/20 | 0.52 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.47 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.46 |
| ▸ | CDK4 | P11802 | 1/20 | 0.46 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.46 |
| ▸ | CCND1 | P24385 | 1/20 | 0.46 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.46 |
| ▸ | SLC26A4 | O43511 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10452980 | 0.85 | MAOB (0.65) | MAOBKMT2AACHEFFAR1KDM4E | |
| SCHEMBL8264422 | 0.84 | MAOB (0.64) | MAOBKMT2AACHEFFAR1KDM4E | |
| SCHEMBL10865258 | 0.83 | MAOB (0.68) | MAOBKMT2AACHEFFAR1KDM4E | |
| Hydrochloric Acid SCHEMBL23235866 | 0.82 | MAOB (0.62) | MAOBKMT2AACHEFFAR1KDM4E | |
| SCHEMBL11860320 | 0.81 | MAOB (0.61) | MAOBKMT2AACHEFFAR1KDM4E | |
| SCHEMBL21340421 | 0.81 | MAOB (0.61) | MAOBKMT2AAPPACHEFFAR1 | |
| SCHEMBL28624803 | 0.81 | MAOB (0.61) | MAOBKMT2AAPPACHEFFAR1 | |
| SCHEMBL22874624 | 0.79 | MAOB (0.58) | MAOBKMT2AAPPACHEFFAR1 | |
| SCHEMBL23235776 | 0.79 | MAOB (0.59) | MAOBKMT2AACHEFFAR1KDM4E | |
| SCHEMBL9558087 | 0.79 | MAOB (0.58) | MAOBKMT2AACHEFFAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2486005-B1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2014-06-18 | — | — | EP | disclosed |
| US-8288404-B2 | Pyrrolidine GPR40 modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2486005-A1 | PYRROLIDINE GPR40 MODULATORS | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| CN-102639495-A | Pyrrolidine GPR40 Modulators | BRISTOL MYERS SQUIBB CO | 2012-08-15 | — | — | CN | disclosed |
| WO-2011044073-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082165-A1 | PYRROLIDINE GPR40 MODULATORS | GPR55, GPR65, GPR27 | MAOB 4128/4885KMT2A 3563/4885APP 3947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.